KRAS and cancer: In this study, we observed that cancer cells resistant to KRAS G12C inhibitors also display cross-resistance to other targeted therapies such as inhibitors of epidermal growth factor receptor (EGFR), insulin-like growth factor 1 receptor (IGF1R), MEK, PI3K, or SHP2.